1. |
Stheneur C, Laffond C, Rioux S, et al. Recent progress in Marfan syndrome. Arch Pediatr, 2012, 19 (5):551-555.
|
2. |
Yuan SM, Jing H. Marfan’s syndrome:an overview. Sao Paulo Med J, 2010,128 (6):360-366.
|
3. |
Lebreiro A, Martins E, Cruz C, et al. Marfan syndrome:clinical manifestations, pathophysiology and new outlook on drug therapy. Rev Port Cardiol, 2010, 29 (6):1021-1036.
|
4. |
Chung AW, Au Yeung K, Sandor GG, et al. Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and-9 in the thoracic aortic aneurysm in Marfan syndrome. Circ Res, 2007, 101 (5):512-522.
|
5. |
Merk DR, Chin JT, Dake BA, et al. miR-29b participates in early aneurysm development in marfan syndrome. Circ Res, 2012, 110 (2):312-324.
|
6. |
Holm TM, Habashi JP, Doyle JJ, et al. Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science, 2011, 332 (6027):358-361.
|
7. |
Brooke BS, Habashi JP, Judge DP, et al. Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome. N Engl J Med, 2008, 358 (26):2787-2795.
|
8. |
Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antag onist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science, 2006, 312 (5770):117-121.
|
9. |
Hartog AW, Franken R, Zwinderman AH, et al. Current and future pharmacological treatment strategies with regard to aortic disease in Marfan syndrome. Expert Opin Pharmacother, 2012, 13 (5):647-662.
|
10. |
Shimizu H, Kasahara H, Nemoto A, et al. Can early aortic root surgery prevent further aortic dissection in Marfan syndrome ? Interact Cardiovasc Thorac Surg, 2012, 14 (2):171-175.
|
11. |
Geisbuesch S, Schray D, Bischoff MS, et al. Frequency of reoperations in patients with Marfan syndrome. Ann Thorac Surg, 2012, 93 (5):1496-1501.
|
12. |
Zhang L, Gao LG, Zhang M, et al. Genotype-phenotype analysis of F-helix mutations at the kinase domain of TGFBR2, including a type 2 Marfan syndrome familial study. Mol Vis, 2012,18:55-63.
|
13. |
Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet, 2003, 33 (3):407-411.
|
14. |
El-HamamsyⅠ, Yacoub MH. Cellular and molecular mechanisms of thoracic aortic aneurysms. Nat Rev Cardiol, 2009, 6 (12):771-786.
|
15. |
ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol, 2007, 8 (11):857-869.
|
16. |
Le Goff C, Cormier-Daire V. From tall to short:the role of TGFβ signaling in growth and its disorders. Am J Med Genet C Semin Med Genet, 2012,160 (3):145-153.
|
17. |
Sengle G, Tsutsui K, Keene DR, et al. Microenvironmental regulation by fibrillin-1. PLoS Genet, 2012,8 (1):e1002425.
|
18. |
Kaartinen V, Warburton D. Fibrillin controls TGF-beta activation. Nat Genet, 2003, 33 (3):331-332.
|
19. |
Yang Y, Cui Y, Peng DQ. ARB May be superior to ACEI on treatment of Marfan’s syndrome by blocking TGF-β mediated activation of ERK. Int J Cardiol, 2012, 155 (3):482-483.
|
20. |
Aalberts JJ, Thio CH, Schuurman AG, et al. Diagnostic yield in adults screened at the Marfan outpatient clinic using the 1996 and 2010 Ghent nosologies. Am J Med Genet A, 2012, 158A (5):982-988.
|
21. |
Radonic T, de Witte P, Baars MJ, et al. Losartan therapy in adults with Marfan syndrome:study protocol of the multi-center randomized controlled compare trial. Trials, 2010,11:3.
|
22. |
Detaint D, Aegerter P, Tubach F, et al. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensinⅡreceptor blocker therapy versus placebo in individuals with Marfan syndrome. Arch Cardiovasc Dis, 2010, 103 (5):317-325.
|
23. |
Gambarin FI, Favalli V, Serio A, et al. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations. J Cardiovasc Med (Hagerstown), 2009, 10 (4):354-362.
|
24. |
Lacro RV, Dietz HC, Wruck LM, et al. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensinⅡreceptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J, 2007, 154 (4):624-631.
|
25. |
Dean JC. Marfan syndrome:clinical diagnosis and management. Eur J Hum Genet, 2007, 15 (7):724-733.
|
26. |
Matt P, Eckstein F. Novel pharmacological strategies to prevent aortic complications in Marfan syndrome. J Geriatr Cardiol, 2011, 8 (4):254-257.
|
27. |
Keane MG, Pyeritz RE. Medical management of Marfan syndrome. Circulation, 2008, 117 (21):2802-2813.
|
28. |
Pyeritz RE, Loeys B. The 8th international research symposium on the Marfan syndrome and related conditions. Am J Med Genet A, 2011,158:42-49.
|